Bicycle Therapeutics (BCYC) Operating Expenses (2018 - 2026)

Bicycle Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $66.4 million for Q1 2026.

• Quarterly Operating Expenses fell 17.23% year-over-year to $66.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $305.8 million (up 11.59% YoY) and the FY2025 annual result came in at $319.7 million, up 30.39% from the prior year.
• Operating Expenses was $66.4 million for Q1 2026 at Bicycle Therapeutics, down from $72.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $89.5 million in Q2 2025 and bottomed at $31.2 million in Q1 2022.
• A 5-year average of $57.6 million and a median of $56.1 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 76.08% — and 2026, when it fell 17.23%.
• Bicycle Therapeutics' Operating Expenses stood at $35.4 million in 2022, then jumped by 68.28% to $59.6 million in 2023, then grew by 19.82% to $71.4 million in 2024, then climbed by 1.81% to $72.7 million in 2025, then slipped by 8.66% to $66.4 million in 2026.
• Business Quant data shows BCYC's Operating Expenses at $66.4 million in Q1 2026, $72.7 million in Q4 2025, and $77.3 million in Q3 2025.